Novartis AG (NYSE:NVS) on Thursday unveiled a sweeping $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. over the next five years.
The move is part of a broader strategy to ensure that all key Novartis medicines for U.S. patients are produced domestically.
As part of the initiative, Novartis will build seven new facilities — four focused on manufacturing and two dedicated to radioligand therapy (RLT) — and expand three existing RLT production sites.
Also Read: Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
These efforts are expected to generate nearly 1,000 new jobs at Novartis and support around 4,000 additional roles.
The move comes after U.S. President Donald Trump on Tuesday disclosed plans for a “major tariff” on foreign pharmaceuticals.
On Wednesday, President Donald Trump announced a 90-day pause on tariffs for countries that have not retaliated against U.S. trade …
Full story available on Benzinga.com
Novartis AG (NYSE:NVS) on Thursday unveiled a sweeping $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. over the next five years.
The move is part of a broader strategy to ensure that all key Novartis medicines for U.S. patients are produced domestically.
As part of the initiative, Novartis will build seven new facilities — four focused on manufacturing and two dedicated to radioligand therapy (RLT) — and expand three existing RLT production sites.
Also Read: Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
These efforts are expected to generate nearly 1,000 new jobs at Novartis and support around 4,000 additional roles.
The move comes after U.S. President Donald Trump on Tuesday disclosed plans for a “major tariff” on foreign pharmaceuticals.
On Wednesday, President Donald Trump announced a 90-day pause on tariffs for countries that have not retaliated against U.S. trade …
Full story available on Benzinga.com
Novartis AG (NYSE:NVS) on Thursday unveiled a sweeping $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. over the next five years.
The move is part of a broader strategy to ensure that all key Novartis medicines for U.S. patients are produced domestically.
As part of the initiative, Novartis will build seven new facilities — four focused on manufacturing and two dedicated to radioligand therapy (RLT) — and expand three existing RLT production sites.
Also Read: Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
These efforts are expected to generate nearly 1,000 new jobs at Novartis and support around 4,000 additional roles.
The move comes after U.S. President Donald Trump on Tuesday disclosed plans for a “major tariff” on foreign pharmaceuticals.
On Wednesday, President Donald Trump announced a 90-day pause on tariffs for countries that have not retaliated against U.S. trade …Full story available on Benzinga.com Read MoreBiotech, Briefs, JNJ, Large Cap, LLY, News, NVS, Stories That Matter, Health Care, General, JNJ, US4781601046, LLY, US5324571083, NVS, US66987V1098, News, Biotech, Large Cap, Health Care, General, Benzinga News
